• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    Adare Pharma Solutions

    Syngene

    Cytovance Biologics

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Adare Pharma Solutions

    Reed-Lane

    Cytovance Biologics

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    FDA Watch

    Inactive Ingredients: Where Guidance Needs to Meet Data

    Looking at FDA’s most recent draft guidance and the struggle with inactive ingredients.

    Inactive Ingredients: Where Guidance Needs to Meet Data
    Related CONTENT
    • Mogene
    • Anti-Counterfeiting in the Pharmaceutical Industry: An Evolution
    • VIDEO: Jubilant's John Teixeira
    • Comprehensive Analytical Services:
    • Vantage Solutions Supports FDA Pilot for Verification Router Service
    Sharif Ahmed, Lachman Consultants Services10.15.19
    The use of inactive ingredients is as dated as the beginning of formulated drugs. Experts now agree that “excipients are neither inert nor inactive substances and depending upon their chemical nature and host factors may produce a variety of undesirable reactions.”1 The good thing is, the regulatory authority that is primarily responsible for the safety of inactive ingredients used in pharmaceutical products intended for the U.S. market has been actively working on ways to improve the availability of information related to inactive ingredients.

    As part of the Food and Drug Administration’s (FDA) mandate, it not only reviews the safety and efficacy of drug products, it also ensures that the inactive ingredients used in the formulations are also safe. A new inactive ingredient, commonly referred to as an excipient, will receive careful review related to its safety. If the FDA has approved an excipient as part of approved drug products for a route of administration, generally it is no longer considered new. Therefore, the excipient may go through less extensive review when the same excipient is used in a new drug product. To make things more efficient and useful for the FDA and the industry, the FDA has been making this review status available for some time in the form of guidance and more recently in the form of a database. This article summarizes the key takeaways from the most recent draft guidance2 on the topic with some historical background of the struggle with inactive ingredients.

    Background
    An article containing 773 ingredients prepared by the FDA in 1982 for use as inactive ingredients was the earliest list of inactive ingredients.3 In 1985, the American Academy of Pediatrics’ Committee on Drugs published an article on “Inactive” Ingredients in Pharmaceutical Products.4 The Committee stated that because of the large number of inactive ingredients and their frequency of use, practicing physicians had become concerned about their possible physiologic effects. “The increasing number of reports of adverse effects associated with pharmaceutical excipients has led to professional and consumer organizations formally requesting the FDA to require complete disclosure on the product label of all substances contained in pharmaceuticals.”5 The article discussed the problems encountered with inactive ingredients and highlighted the specific excipients such as benzyl alcohol, propylene glycol, lactose, coloring agents, sulfites and saccharin.

    In 1987, the FDA prepared and published a list of inactive ingredients in paper format and called it the inactive ingredient guide (IIG).6 The list contained inactive ingredients and the amounts that have previously been reviewed and approved by the FDA for a dosage form and/or particular route of administration. Over time, the list continued to grow as more inactive ingredients and additional details were added. The FDA released the online version of the inactive ingredient database (IID) in 2003.7 Since its release, both industry professionals and the FDA have been using the database. The IID database indicates the maximum potency of a specific excipient based on the route of administration and dosage form. In this fashion, formulators can use the IID database to evaluate the use of potential excipients in their drug product without needing to generate additional safety information. Similarly, when the FDA receives a new drug application (NDA) or an abbreviated new drug application (ANDA), it refers to the IID to see if the proposed excipients in drug product formulations are acceptable or require additional documentation related to safety.8

    However, inactive ingredients continued to be an issue for both the industry and the FDA. In October 2010, the FDA implemented the Substance Registration System (SRS) which had a significant impact on the IID. Concerns were raised regarding how it is managed, and the information utilized for NDA and ANDA drug product reviews. By 2011, the International Pharmaceutical Excipients Council of the Americas (IPEC) had been contacted by a number of both member and non-member companies around the world concerning issues related to changes in the FDA policies on how the IID was to be referenced to determine the acceptable levels of specific grades of excipients.9 IPEC requested and met with the FDA on December 9, 2011, to convey the industry concerns and understand the FDA’s needs. Since then, IPEC and the FDA have met frequently to facilitate the appropriate use of IID listing information.

    In October 2013, the FDA published a draft Guidance for Industry titled “ANDA Submissions - Refuse-to-Receive Standards.”10 The guidance suggested that an excipient is considered justified, for receipt purposes, if the proposed level is at or below the amount indicated in the IID for the corresponding route of administration of the test drug product. If an applicant uses an excipient at a level that is higher than what is listed in the IID, a few options are available. First, an applicant can submit complete pharmacology/toxicology information to support the excipient. Second, cite specific examples of a CDER-approved drug product that contains the inactive ingredient at or above the proposed level of use for the appropriate route of administration. Alternatively, the applicant can submit a Controlled Correspondence requesting an evaluation of the proposed level of use before submission of the ANDA. The final guidance was issued on September 2014.11 As the generic drug industry was facing new challenges in drug development, the FDA indicated that it had developed a prototype IID database to improve the IID. The enhanced database includes the Maximum Daily Intake (MDI) of excipients in addition to the potency per unit used in the current IID.12

    In April 2015, IPEC published a position paper on FDA’s Inactive Ingredient Database.13 In it, IPEC articulated its position on the current state of the IID and FDA’s use of the data in the IID to determine acceptance of ANDAs. IPEC stated that “pharmaceutical companies have encountered longer review cycles, unnecessary requests for additional safety studies/information and/or Refuse to Receive letters from the Agency.”14 IPEC recommended that the FDA “institute policies based on sound science and risk for using IID information in the evaluation of ANDA applications.”15

    With the authorization of GDUFA II, the FDA published a commitment letter regarding its performance goals and program enhancements for fiscal years 2018-2022.16 The commitment letter included the following goals for the IID: “By October 1, 2020, FDA will complete enhancements to the IID so users can perform electronic queries to obtain accurate Maximum Daily Intake and Maximum Daily Exposure information for each route of administration for which data is available FDA will update the IID on an ongoing basis and post quarterly notice of updates made. Such notices will include each change made and, for each change, the information replaced.”17 As a first step toward that goal, the FDA published the draft guidance, “Using the Inactive Ingredient Database,” in July 2019.18 

    The Draft Guidance: Using the Inactive Ingredient Database
    The guidance describes how the industry can use the IID to evaluate excipient levels that are safe for use in new formulations. It describes the structure, nomenclature, maximum potency levels, and units of measure used in the IID. The FDA enters all drug formulations into the Agency’s internal master database as part of the application record. On the other hand, the FDA creates the IID based on a subset of information from the internal master database and makes it publicly available. The IID lists the largest value of an excipient for each route of administration and dosage form available from the FDA’s master database. However, IID does not reveal the formulation or identify the product. This value appears as the maximum potency listed for the excipient for that route of administration and dosage form. At times, the FDA removes entries from the IID if the Agency has reason to question the safety of excipients, or to correct information. The removal usually happens when drug products are reformulated or withdrawn from sale for safety reasons that implicate the excipients. The implication is that an excipient may remain on the database if the corresponding drug product is reformulated or withdrawn from sale, not for safety reasons or the safety issue is not due to the excipient. If someone needed to look up previously published versions of the IID for an ingredient, archival files from 2009 to present, can be downloaded through the IID web page.

    The IID displays the preferred term for the excipient as it appears in Global Substance Registration System (GSRS) to promote consistency in nomenclature in the IID. Most entries in the IID are distinguished with a unique ingredient identifier (UNII), which is generated by GSRS. The UNII also facilitates Structured Product Labeling (SPL), which includes UNIIs for all excipients. The guidance defines the maximum potency as the highest level of the excipient per dosage unit in each dosage form in which it is used. The FDA provided an example in the guidance to illustrate the difference between the maximum potency and maximum daily exposure (MDE). Since the units of measure differ for different dosage forms, the FDA attempted to clarify the unit of measure for various dosage forms. For example, maximum potency for solid oral dosage forms is listed as weight. Liquid oral dosage forms are listed as weight per volume and topical products are listed in percentage weight/weight or weight/volume. Finally, parenteral dosage forms are listed as percentage weight per volume.

    Although applicants of Investigational New Drug Applications (INDs), NDAs, and ANDAs review the IID to help justify the levels of excipients in their formulations, INDs and NDAs usually include nonclinical or clinical studies conducted with the excipients or proposed studies may provide safety data. Generally, excipients proposed for a generic drug are first reviewed by the FDA when the ANDA is assessed during filing review. For ANDA filings, applicants can refer to the appropriate level of the excipient listed in the current IID. If the applicant is proposing a level higher than that is listed in the IID, a justification supporting the safety of the excipient at the proposed level may get the application accepted for filing. When referencing an IID listing that differs from the proposed excipient in nomenclature, molecular weight, viscosity, or grade, applicants should justify citing the IID listing as the basis for the excipient and its proposed level of use. However, the multidisciplinary review of the safety of the excipients proposed is done during the technical review of the application. If a reference to the IID and any additional information submitted by the applicant is not satisfactory, the FDA may request safety information. However, one should keep in mind that when an excipient requires clinical investigations to establish the safety of the excipient, that drug product would not be permitted in an ANDA.

    The guidance also discusses the options available for the industry to communicate with the FDA. Other than contacting the FDA via email to fda-gsrs@fda.hhs.gov for UNII related requests or to iidupdate@fda.hhs.gov for IID listings, reports of errors, or clarifications, applicants may submit application-specific questions about the acceptability of excipient levels, to the Agency as a Controlled Correspondence. The industry has been using this as the primary mode of communication regarding inactive ingredients. The FDA has provided helpful and detailed information on various topics that are covered under the scope of controlled correspondence in the guidance for industry on Controlled Correspondence.20 Unfortunately, the Controlled Correspondences are processed in accordance with current GDUFA timelines that are not helpful for the fast pace of generic drug development and the responses are not always specific for legal or confidentiality reasons.

    What to Expect
    As expected, this guidance does not provide much more in terms of what is coming down the pike. The FDA has been providing bits and pieces of hints in terms of what to expect. In phase I of this enhancement initiative, new data standards such as the route of administration (ROA), dosage form (DF) and units of measure (UOM) will be applied.21 Once the unit of measures (UOM) are standardized within the database, numeric potency values can be accurately compared for each excipient by ROA and DF combination. The advantage of converting to SPL terminology is evident as there are fewer terms for ROA and DF.  One other benefit for frequent users of the database is a change log that identifies changes made in each publication.

    One thing is for sure, by October 2020, the IID will include the MDE of excipients for which it is available. Note that only MDE, rather than maximum potency for those excipients, will be listed, if available. What is not clear is that in the absence of an MDE, will maximum potency still be listed? The user-friendly IID interface may not provide all the answers right away, but at a minimum, we will be able to obtain the MDE in a matter of a few clicks for most excipients. 

    References
    1. Kumar, A., “Adverse effects of pharmaceutical excipients”, Lippincott, Williams and Wilkins, Adverse Drug Reaction Bulletin, October 2003, No. 222
    2. U.S. Food and Drug Administration, “Using the Inactive Ingredient Database – Guidance for Industry”, Draft Guidance, July 2019
    3. Brown, J.L., “Incomplete labeling of pharmaceuticals: A list of “inactive” ingredients”, N Engl J Med, 1983, 309(7):439-441
    4. American Academy of Pediatrics – Committee on Drugs, “‘Inactive’ Ingredients in Pharmaceutical Products”, Pediatrics, 1985, 76: 635-643
    5. Id
    6. U.S. Food and Drug Administration, “Using the Inactive Ingredient Database – Guidance for Industry”, Draft Guidance, July 2019
    7. Id.
    8. Id.
    9. The International Pharmaceutical Excipients Council of Americas, – “Inactive Ingredient Database Issues with ANDAs: Backgrounder Document”, IPEC – FDA OGD Meeting, December 9, 2011
    10. U.S Food and Drug Administration, “Guidance for Industry – ANDA Submissions - Refuse-to-Receive Standards”, Draft Guidance, October 2013
    11. U.S Food and Drug Administration, “Guidance for Industry – ANDA Submissions – Refuse-to-Receive Standards”, September 2014
    12. Naiqi, Y., “Inactive Ingredient Database – FDA Update”, The USP Excipients Stakeholder Forum, June 18, 2014
    13. The International Pharmaceutical Excipients Council of Americas, “IPEC-Americas Publishes Position Paper on FDA Inactive Ingredient Database”, April 22, 2015
    14. Id
    15. Id
    16. U.S. Food and Drug Administration, “GDUFA II Commitment Letter: GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2018-2022”, May 12, 2016
    17. Id.
    18. U.S. Food and Drug Administration, “Using the Inactive Ingredient Database – Guidance for Industry”, Draft Guidance, July 2019
    19. Id
    20. U.S. Food and Drug Administration, “Controlled Correspondence Related to Generic Drug Development – Guidance for Industry”, September 2015
    21. U.S. Food and Drug Administration, Most Recent Changes to the IID Database, Current as of 05/06/2019

    Sharif Ahmed
    Lachman Consultants Services

    Sharif Ahmed is a Principal Consultant in the Regulatory Practice at Lachman Consultants with nearly 30 years of progressive responsibilities in the pharmaceutical industry who is knowledgeable of the product approval processes of U.S. FDA and Health Canada.
    Related Searches
    • Dosage
    • labeling
    • Development
    • canada
    Suggested For You
    Mogene Mogene
    Anti-Counterfeiting in the Pharmaceutical Industry: An Evolution Anti-Counterfeiting in the Pharmaceutical Industry: An Evolution
    VIDEO: Jubilant VIDEO: Jubilant's John Teixeira
    Comprehensive Analytical Services: Comprehensive Analytical Services:
    Vantage Solutions Supports FDA Pilot for Verification Router Service Vantage Solutions Supports FDA Pilot for Verification Router Service
    Quality Metrics Feedback Quality Metrics Feedback
    Continuous Manufacturing and its Regulatory Challenge Continuous Manufacturing and its Regulatory Challenge
    Drug Discovery Technology Trends Drug Discovery Technology Trends
    Q BioMed, Chemveda Form Cancer Collaboration Q BioMed, Chemveda Form Cancer Collaboration
    FDA Extends CRADA with CluePoints FDA Extends CRADA with CluePoints
    Lonza, Celltrion Sign Contract to Manufacture Remsima Drug Substance Lonza, Celltrion Sign Contract to Manufacture Remsima Drug Substance
    Embracing Risk-Based Monitoring: The Pivotal Role of Tools and Technologies  Embracing Risk-Based Monitoring: The Pivotal Role of Tools and Technologies
    NIIMBL, FDA to Advance Innovation in Bio Manufacturing NIIMBL, FDA to Advance Innovation in Bio Manufacturing
    FDA Accepts RedHill Biopharma’s NDA for Talicia FDA Accepts RedHill Biopharma’s NDA for Talicia
    Biopharma Trends & CDMOs Biopharma Trends & CDMOs

    Related FDA Watch

    • Solid Dosage/Creams/Ointments
      Recent Advances in Solid Dispersion Technologies

      Recent Advances in Solid Dispersion Technologies

      Improving the bioavailability and therapeutic efficiency of poorly soluble drugs.
      José L. Toro, Directory, Lachman Consultants 01.27.21

    • The Importance of Hypothesis Testing During Investigations

      The Importance of Hypothesis Testing During Investigations

      Why it is critical to have controls in place during out-of-specification investigations to provide quality assurance.
      Paul Mason, PhD, Lachman Consultants 11.17.20

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      Ensuring Manufacturing Continuity for Essential Medicines

      Ensuring Manufacturing Continuity for Essential Medicines

      Applying the principles of Quality Risk Management to get medicines to market faster.
      John Darby, M.Sc., Senior Director, Lachman Consultant Services, Inc. 09.09.20


    • Biologics, Proteins, Vaccines
      Pharma’s Fight Against the Coronavirus Pandemic

      Pharma’s Fight Against the Coronavirus Pandemic

      A look at the pharma industry’s concerted effort to develop vaccines against the SARS-CoV-2 virus and therapeutics to treat COVID-19.
      Keith O. Webber, Lachman Consultant Services, Inc. 07.15.20

    • Information Technology | Regulatory Affairs
      Data Integrity: Beyond Electronic Records

      Data Integrity: Beyond Electronic Records

      Get your Data Integrity house in order
      Tim Rhines, Ph.D., Director, Lachman Consultant Services, Inc. 05.05.20

    • Regulatory Affairs
      Inquiring Minds Want to Know, Just Ask FDA

      Inquiring Minds Want to Know, Just Ask FDA

      What you need to know prior to submission
      Michelle Ryder, Lachman Consultant 04.01.20


    • Regulatory Affairs
      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      The Art of Filing NDA/ANDA Post-Approval Changes to the FDA

      Some tips to make your trip along the regulatory pathway to report manufacturing changes easier.
      Amy Schutte, Senior Associate, Lachman Consultant Services 03.04.20

    • Regulatory Affairs
      Continuous Manufacturing and its Regulatory Challenge

      Continuous Manufacturing and its Regulatory Challenge

      ...
      José L. Toro, PhD, Lachman Consultants 09.16.19

    • QA/QC | Validation
      Considerations for Analytical Method Validation Lifecycle Controls

      Considerations for Analytical Method Validation Lifecycle Controls

      ICH is set to implement new regulatory guidance dedicated to analytical method development
      Paul Mason, PhD, Lachman Consultants 07.15.19


    • Regulatory Affairs
      Effective Post Market Supplier Strategy for Combination Products

      Effective Post Market Supplier Strategy for Combination Products

      Combinations are typically designed, developed and maintained under a robust contract manufacturing process
      Lori-Ann Woodard CBA, CQE, CSQE, Lachman Consultant Services 06.13.19

    • QA/QC
      Nitrosamines

      Nitrosamines

      How to address these unwelcome guests in the pharmaceutical world
      Aloka Srinivasan, Ph.D., Lachman Consultant Services 05.07.19

    • Regulatory Affairs
      KASA to Support Generic Drug Review

      KASA to Support Generic Drug Review

      FDA expects the new system to advance OPQ’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs.
      Sharif Ahmed, Lachman Consultant Services 04.05.19


    • Regulatory Affairs
      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      FDA’s Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition an

      A look at how the FDA will administer the transition of NDAs to BLAs
      Keith Webber, Ph.D., Lachman Consultant Services 03.06.19

    • Regulatory Affairs
      Reporting CPPs to FDA

      Reporting CPPs to FDA

      Importance of identifying critical process parameters in original submissions to FDA.
      Aloka Srinivasan, Ph.D. Lachman, Consultant Services 10.10.18

    • Regulatory Affairs
      FDA and Field Alert Reports

      FDA and Field Alert Reports

      Analysis of “Field Alert Report Submission Questions and Answers Guidance for Industry”
      Constance Richard-Math, Lachman Consultants 09.11.18

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login